News | April 24, 2008

MRA Contrast Agent Meets Endpoints in Study

April 25, 2008 - EPIX Pharmaceuticals Inc. met all pre-specified endpoints prospectively agreed to with the FDA in a blinded, independent re-read of images of its novel blood pool magnetic resonance angiographic (MRA) agent, Vasovist (gadofosveset trisodium), and plans to resubmit a New Drug Application (NDA) to the FDA for Vasovist in mid-2008.

There are currently no contrast agents approved in the United States for use with MRA, a noninvasive modality for imaging blood vessels. However, it is estimated that approximately 1.5 million MRAs will be conducted in the U.S. during 2008 using gadolinium-based products.

"We believe these positive results confirm the efficacy upon which the NDA was based and allow us to move forward with our strategy of achieving U.S. regulatory approval," said Andrew Uprichard, M.D., president and head of research and development at EPIX. "We worked closely with the FDA to design the protocol and statistical analysis plan for the re-read of these images and look forward to continuing our work with the FDA to bring Vasovist to market in the United States."

The company said it believes these positive results position it well for FDA approval and, if approved, will serve a large and unmet need in the U.S. MRA market. The company hopes to work with the FDA to achieve approval for Vasovist by the end of 2008. Currently, there are no MRA imaging agents approved in the United States, however, unapproved gadolinium-based agents are used for MRA. Vasovist is currently approved for marketing in 33 countries.

For more information: www.epixpharma.com

Related Content

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Overlay Init